Patents Examined by Phyllis G. Spivack
  • Methods for the treatment and amelioration of atopic dermatitis
    Patent number: 7998945
    Abstract: The present invention relates to a method for the treatment and/or amelioration of atopic dermatitis, the method including the administration of a pharmaceutically active dose of a compound selected from miltefosine, edelfosine, perifosine and ilmofosine to a subject in need of such a treatment and/or amelioration.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: August 16, 2011
    Assignee: Jado Technologies GmbH
    Inventors: Tobias Braxmeier, Tim Friedrichson, Gary Jennings
  • Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde
    Patent number: 7989501
    Abstract: The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 2, 2011
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Susan D. Mertins, Susan Elaine Bates, David G. Covell, Geoffrey W. Patton, Melinda G. Hollingshead, Rao Vishnuvajjalla
  • Combination of anticholineric and ? mimetics for the treatment of respiratory diseases
    Patent number: 7985766
    Abstract: The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a ? mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: July 26, 2011
    Assignee: MEDA Pharma GmbH & Co. KG
    Inventors: Joachim Goede, Joachim Maus, Peter Jurgen Cnota, Istvan Szelenyi
  • Compositions and methods for inhibiting gastric acid secretion
    Patent number: 7981908
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: July 19, 2011
    Assignee: Vecta, Ltd.
    Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
  • Diarylmethylpiperazines as therapeutic agents for viral myocarditis
    Patent number: 7968549
    Abstract: To provide a therapeutic agent for viral myocarditis and viral myocarditis-related viral diseases by treating the occurrence of cell damage in various organs regardless of the type of virus. A therapeutic agent for viral myocarditis and viral myocarditis-related viral diseases is provided that has as an active ingredient 2-[4-(dipehnylmethyl)-1-piperazinyl]-acetic acid, amide derivative, individual optical isomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: June 28, 2011
    Inventor: Akira Matsumori
  • Use of mGluR5 antagonists for the treatment of gerd
    Patent number: 7964609
    Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Anders Lehmann, Jan Mattsson, Thomas M. Stormann
  • Method for the treatment of psoriasis
    Patent number: 7964588
    Abstract: A method for the therapeutic treatment of psoriasis by the administration of an anti-psoriasis effective amount of Doxivir (CTC-96) is discloses.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: June 21, 2011
    Assignee: Redox Phamaceutica Co., Inc.
    Inventor: David Gershon
  • Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome
    Patent number: 7960429
    Abstract: The present invention concerns methods useful in treating a subject having diarrhea-predominant IBS (IBS-D) by administering N methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof to the subject.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: June 14, 2011
    Assignee: Tioga Pharmaceuticals, Inc
    Inventor: Allen Mangel
  • Long-chain inulin
    Patent number: 7959962
    Abstract: The invention relates to long-chain inulin and its preparation from artichoke roots, its use in foodstuffs and cosmetic preparations and foodstuffs and cosmetic preparations having the long-chain inulin.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: June 14, 2011
    Assignee: Bayer CropScience AG
    Inventors: Elke Hellwege, Roger Peeters, Jens Pilling
  • Method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia with a 1-methylnicotinamide salt
    Patent number: 7935717
    Abstract: The invention is directed to a method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia by administration of a 1-methylnicotinamide salt.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: May 3, 2011
    Assignee: Pharmena Spolka Akcyjna (Pharmena S.A.)
    Inventors: Jerzy Gebicki, Stefan Chlopicki
  • Method for treating colonic viscerosensitivity and spasticity
    Patent number: 7932286
    Abstract: There is provided a method of reducing pain associated with colonic viscerosensitivity and spasticity induced during a colonic examination chosen from colonic endoscopy, barium/air contrast colonic radiography and virtual colonoscopy of a non-sedated patient.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: April 26, 2011
    Inventor: François Martin
  • Methods for the amelioration of episodes of acute or chronic ulcerative colitis
    Patent number: 7928132
    Abstract: Methods of ameliorating episodes of accute or chronic colitis are provided by using methimazole derivatives and tautomeric cyclic thiones in combination with another pharmaceutical compound.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: April 19, 2011
    Assignee: Ohio University
    Inventors: Leonard D. Kohn, Douglas J. Goetz, Uruguaysito Benavides-Peralta, Mariana Gonzalez-Murguiondo, Norikazu Harii, Christopher J. Lewis, Giorgio Napolitano, Nilesh D. Dagia
  • Methods of treating travelers diarrhea and hepatic encephalopathy
    Patent number: 7928115
    Abstract: Treatment of traveler's diarrhea in subjects having hepatic encephalopathy using rifaximin is disclosed.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: April 19, 2011
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: William Forbes, Enoch Bortey
  • Use of cyclipostin derivatives for the treatment of mycobacterial infectious diseases
    Patent number: 7923438
    Abstract: The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria, nocardia or corynebacteria, wherein E is phosphorus; X1, X2 and X3 are oxygen; and R1 and R2 are as defined in the specification.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: April 12, 2011
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Seibert, Luigi Toti, Joachim Wink
  • Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
    Patent number: 7910617
    Abstract: A method for suppressing the number of peripheral blood lymphocytes involving administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof, such as the hydrochloride salt.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: March 22, 2011
    Assignee: Sankyo Company, Limited
    Inventors: Takahide Nishi, Toshiyasu Takemoto, Shojiro Miyazaki, Takaichi Shimozato, Futoshi Nara, Takashi Izumi
  • Therapeutic methods using prostaglandin EPagonist components
    Patent number: 7893107
    Abstract: Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to afflicted with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastropathy, non-steroidal anti-inflammatory drug-induced enteropathy and intestinal ischemia. Such administration results in treating the disease or condition.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: February 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Guang-Liang Jiang, Wha Bin Im, Larry A. Wheeler
  • Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
    Patent number: 7893091
    Abstract: This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3 -yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: February 22, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Keith M. Gottesdiener, Stuart A. Green, Euan MacIntyre
  • Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
    Patent number: 7879898
    Abstract: Methods are provided for treating chronic obstructive pulmonary diseases such as emphysema using compounds that activate the signaling pathways of hepatocyte growth factor.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: February 1, 2011
    Assignee: Angion Biomedica Corp.
    Inventor: Yanchun He
  • Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
    Patent number: 7879870
    Abstract: Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with a therapeutically effective dose less than 50 mg. of opioid antagonists (e.g., naltrexone, nalmefene or naloxone) are disclosed. An embodiment of the invention includes a method of pharmaceutical treatment comprising orally administering to a human subject having Crohn's disease or ulcerative colitis a therapeutic pharmaceutical composition once per day in the evening or at bedtime, wherein the pharmaceutical composition comprises form about 3 mg to about 4.5 mg of naltrexone, nalmefene, naloxone, or a hydrochloride salt thereof in an immediate release solid dosage formulation.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: February 1, 2011
    Inventors: Jill P. Smith, Ian S. Zagon, Moshe Rogosnitzky
  • N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
    Patent number: 7875648
    Abstract: The invention relates to a method of treating muscular dystrophy, such as a muscular dystrophy or myopathy resulting from mutations in genes encoding collagen VI, in a mammal. The method involves administering of a compound of the formula (I) or a pharmaceutically acceptable addition salt thereof to the mammal.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: January 25, 2011
    Assignee: Santhera Pharmaceuticals (Schweiz) AG
    Inventor: Thomas Meier